1Stanulla M, Carlo G, Meissner B, et al. Intergrating molecular information into treatment of childhood acute lymphoblastic leukemia perspective from the BFM study group [ J]. Blood cells Mol Dis, 2007,39(2) : 160-163.
2Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia [ J ]. Blood, 2003,102 ( 8 ) :2756-2762.
3Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children: Oncology Group study [ J ]. Blood, 2008,111 (12) :5477-5485.
4Vora A, Mitchell CD, Lennard L,et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia : a randomised trial. Lancet,2006,368 : 1339-1348.
5Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood,2007,109:896-904.
6Pui C H, Sandlund JT, Pei D,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study ⅩⅢB at St Jude Children' s Research Hospital. Blood,2004,104 : 2690-2696.
7Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Bedin-Frankfurt-Muenster protocol Ⅱ. Blood, 2002,100:420-426.
8Schrappe M, Reiter A, Ludwig WD,et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood,2000, 95:3310-3322.
9Zhou J, Goldwasser MA, Li A,et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood ,2007,110 : 1607-1611.
10Raft T, G~kbuget N, Ltischen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment : data from the GMALL 06/99 and 07/03 trials. Blood,2007,109:910-915.
8Kim H, Suzuki H, Matsuoka M, et al. Molecular mechanism of the acquisition of new- quinolone resistance in myeobacterium ieprae and mtubereulosis and rapid differentiation methods for resistant bacilli[J]. Nihon Hansenbyo Gakkai Zasshi, 2011,80 (1) :17-27.
9Shinagawa N,Hasegawa M, Hirata K,et al. Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents- special references to bacteria isolated between April 2008 and March 2009[J].Jpn J Antihiot,2010, 63(2):105- 170.
10Liu Y, Chert J, Tang J, et al. Cost ot childhood acute lymphoblastic leukemia care in Shanghai, China. Pediatr Blood Cancer, 2009,53 : 557-562.
